Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone Starts Phase III Trial of PD-L1 Candidate in Gastric Cancer Patients

publication date: Apr 19, 2019

CStone Pharma of Shanghai has started a China Phase III of its anti-PD-L1 antibody (CS1001) as a first-line treatment for gastric cancer. The specific indications for the trial are gastric adenocarcinoma (GC) or gastro-esophageal junction (GEJ) adenocarcinoma, which comprise over 90% of all gastric cancer cases. The multi-center, placebo-controlled trial will evaluate the efficacy and safety of CS1001 plus XELOX chemotherapy in patients with unresectable, locally advanced, or metastatic GC or GEJ adenocarcinoma. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.